Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Lenalidomide Oral Suspension vs Capsule
NCT02521714Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lenalidomide in multiple myeloma (MM) and myelodysplastic syndromes (MDS) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 5 more. Started Aug 2015; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT02521714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521714.